RU2371198C2 - Улучшенная вспомогательная терапияопухолей, экспрессирующих g250 - Google Patents
Улучшенная вспомогательная терапияопухолей, экспрессирующих g250 Download PDFInfo
- Publication number
- RU2371198C2 RU2371198C2 RU2007104040/14A RU2007104040A RU2371198C2 RU 2371198 C2 RU2371198 C2 RU 2371198C2 RU 2007104040/14 A RU2007104040/14 A RU 2007104040/14A RU 2007104040 A RU2007104040 A RU 2007104040A RU 2371198 C2 RU2371198 C2 RU 2371198C2
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- antigen
- treatment
- use according
- patients
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 83
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 10
- 238000011282 treatment Methods 0.000 claims abstract description 52
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims abstract description 42
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 claims abstract description 38
- 239000000427 antigen Substances 0.000 claims abstract description 37
- 102000036639 antigens Human genes 0.000 claims abstract description 37
- 108091007433 antigens Proteins 0.000 claims abstract description 37
- 206010061289 metastatic neoplasm Diseases 0.000 claims abstract description 16
- 230000000683 nonmetastatic effect Effects 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 19
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 238000009098 adjuvant therapy Methods 0.000 claims description 12
- 238000001802 infusion Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 230000009545 invasion Effects 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000007660 Residual Neoplasm Diseases 0.000 claims description 4
- 208000019065 cervical carcinoma Diseases 0.000 claims description 4
- 101100282617 Bovine herpesvirus 1.1 (strain Cooper) gC gene Proteins 0.000 claims description 3
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 230000027455 binding Effects 0.000 claims description 3
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 201000005296 lung carcinoma Diseases 0.000 claims description 3
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 201000007180 bile duct carcinoma Diseases 0.000 claims description 2
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 238000002224 dissection Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 description 39
- 201000010099 disease Diseases 0.000 description 23
- 238000000034 method Methods 0.000 description 20
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 17
- 206010027476 Metastases Diseases 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- 210000001165 lymph node Anatomy 0.000 description 13
- 238000013059 nephrectomy Methods 0.000 description 10
- 230000034994 death Effects 0.000 description 9
- 231100000517 death Toxicity 0.000 description 9
- 230000009790 vascular invasion Effects 0.000 description 9
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 238000004393 prognosis Methods 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 108010047761 Interferon-alpha Proteins 0.000 description 6
- 102000006992 Interferon-alpha Human genes 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108700012439 CA9 Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010038389 Renal cancer Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003195 fascia Anatomy 0.000 description 4
- 201000010982 kidney cancer Diseases 0.000 description 4
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 102000003846 Carbonic anhydrases Human genes 0.000 description 3
- 108090000209 Carbonic anhydrases Proteins 0.000 description 3
- 238000011360 adjunctive therapy Methods 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000000058 Anaplasia Diseases 0.000 description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 101710160107 Outer membrane protein A Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000001855 preneoplastic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 229940124148 Macrophage inhibitor Drugs 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 238000011353 adjuvant radiotherapy Methods 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 201000010231 gastrointestinal system cancer Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 230000029219 regulation of pH Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004231 tunica media Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58467904P | 2004-07-02 | 2004-07-02 | |
| US60/584,679 | 2004-07-02 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009122344/15A Division RU2519340C2 (ru) | 2004-07-02 | 2009-06-10 | Улучшенная вспомогательная терапия опухолей, экспрессирующих g250 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007104040A RU2007104040A (ru) | 2008-08-10 |
| RU2371198C2 true RU2371198C2 (ru) | 2009-10-27 |
Family
ID=35431139
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007104040/14A RU2371198C2 (ru) | 2004-07-02 | 2005-06-29 | Улучшенная вспомогательная терапияопухолей, экспрессирующих g250 |
| RU2009122344/15A RU2519340C2 (ru) | 2004-07-02 | 2009-06-10 | Улучшенная вспомогательная терапия опухолей, экспрессирующих g250 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009122344/15A RU2519340C2 (ru) | 2004-07-02 | 2009-06-10 | Улучшенная вспомогательная терапия опухолей, экспрессирующих g250 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7691375B2 (enExample) |
| EP (2) | EP1763367A2 (enExample) |
| JP (1) | JP2008505143A (enExample) |
| KR (1) | KR101205289B1 (enExample) |
| CN (1) | CN101052416B (enExample) |
| AU (1) | AU2005259481B2 (enExample) |
| BR (1) | BRPI0512854A (enExample) |
| CA (1) | CA2566950A1 (enExample) |
| DK (1) | DK2497497T3 (enExample) |
| ES (1) | ES2641089T3 (enExample) |
| MX (1) | MXPA06013240A (enExample) |
| RU (2) | RU2371198C2 (enExample) |
| WO (1) | WO2006002889A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2442983C1 (ru) * | 2011-01-14 | 2012-02-20 | Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы | Способ прогнозирования безрецидивной выживаемости по молекулярным факторам у больных с метастазами колоректального рака в печени после ее резекции |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077081A1 (en) * | 2001-02-07 | 2004-04-22 | Egbert Oosterwijk | Hybridoma cell line g250 and its use for producing monoclonal antibodies |
| US20090162382A1 (en) * | 2002-03-01 | 2009-06-25 | Bernett Matthew J | Optimized ca9 antibodies and methods of using the same |
| AU2003280442B2 (en) * | 2002-07-01 | 2009-02-05 | Wilex Ag | Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas |
| WO2011034182A1 (ja) | 2009-09-18 | 2011-03-24 | 三菱化学株式会社 | 肝細胞癌マーカー |
| AU2013328580B2 (en) | 2012-10-12 | 2016-01-21 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| NZ712023A (en) * | 2013-02-22 | 2019-10-25 | Wilex Ag | Caix stratification based cancer treatment |
| CN105209077B (zh) | 2013-03-13 | 2019-06-11 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓以及其结合物 |
| EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US20200023072A1 (en) | 2016-10-11 | 2020-01-23 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| AU2021362997A1 (en) | 2021-11-03 | 2024-05-16 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988008854A1 (en) * | 1987-05-06 | 1988-11-17 | Egbert Oosterwijk | Monoclonal antibodies to renal cell carcinoma |
| RU2257200C1 (ru) * | 2004-05-12 | 2005-07-27 | Кутушов Михаил Владимирович | Лекарственное средство |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5387676A (en) * | 1992-03-11 | 1995-02-07 | Ciba Corning Diagnostics Corp. | MN gene and protein |
| US6417337B1 (en) * | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
| ES2531909T3 (es) * | 2001-02-07 | 2015-03-20 | Wilex Ag | Método de producción de anticuerpos recombinantes contra tumores |
| WO2003068920A2 (en) | 2002-02-13 | 2003-08-21 | Ludwig Institute For Cancer Research | Humanized gm-csf antibodies |
| AU2003280442B2 (en) * | 2002-07-01 | 2009-02-05 | Wilex Ag | Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas |
-
2005
- 2005-06-29 AU AU2005259481A patent/AU2005259481B2/en not_active Expired
- 2005-06-29 JP JP2007519679A patent/JP2008505143A/ja active Pending
- 2005-06-29 WO PCT/EP2005/006994 patent/WO2006002889A2/en not_active Ceased
- 2005-06-29 MX MXPA06013240A patent/MXPA06013240A/es active IP Right Grant
- 2005-06-29 US US11/630,170 patent/US7691375B2/en active Active
- 2005-06-29 ES ES12171081.8T patent/ES2641089T3/es not_active Expired - Lifetime
- 2005-06-29 RU RU2007104040/14A patent/RU2371198C2/ru not_active IP Right Cessation
- 2005-06-29 BR BRPI0512854-4A patent/BRPI0512854A/pt not_active Application Discontinuation
- 2005-06-29 CA CA002566950A patent/CA2566950A1/en not_active Abandoned
- 2005-06-29 CN CN2005800205034A patent/CN101052416B/zh not_active Expired - Fee Related
- 2005-06-29 EP EP05775970A patent/EP1763367A2/en not_active Ceased
- 2005-06-29 EP EP12171081.8A patent/EP2497497B1/en not_active Expired - Lifetime
- 2005-06-29 KR KR1020067027704A patent/KR101205289B1/ko not_active Expired - Fee Related
- 2005-06-29 DK DK12171081.8T patent/DK2497497T3/en active
-
2009
- 2009-06-10 RU RU2009122344/15A patent/RU2519340C2/ru not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988008854A1 (en) * | 1987-05-06 | 1988-11-17 | Egbert Oosterwijk | Monoclonal antibodies to renal cell carcinoma |
| RU2257200C1 (ru) * | 2004-05-12 | 2005-07-27 | Кутушов Михаил Владимирович | Лекарственное средство |
Non-Patent Citations (1)
| Title |
|---|
| KAWATA N. et al Immunological effect of recombinant interferon-gamma in renal cell carcinoma // Hinyokika Kiyo. 1993 Jun; 39(6):511-5. реферат, он-лайн [Найдено в Интернет на www.pubmed.com 20.10.2008], PMID: 8337976 [PubMed - indexed for MEDLINE]. BLEUMER I et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients // Br J Cancer. 2004 Mar 8; 90(5):985-90. реферат, он-лайн [Найдено в Интернет на www.pubmed.com 20.10.2008], PMID: 14997194 [PubMed-indexed for MEDLINE] OOSTERWIJK E. et al. Monoclonal antibody-based therapy for renal cell carcinoma. // Urol Clin North Am. 2003 Aug; 30(3):623-31. реферат, он-лайн [Найдено в Интернет на www.pubmed.com 08.10.2008], PMID: 12953760 [PubMed - indexed for MEDLINE]. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2442983C1 (ru) * | 2011-01-14 | 2012-02-20 | Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы | Способ прогнозирования безрецидивной выживаемости по молекулярным факторам у больных с метастазами колоректального рака в печени после ее резекции |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2009122344A (ru) | 2010-12-20 |
| AU2005259481B2 (en) | 2010-04-22 |
| US20070207157A1 (en) | 2007-09-06 |
| CA2566950A1 (en) | 2006-01-12 |
| US7691375B2 (en) | 2010-04-06 |
| DK2497497T3 (en) | 2017-08-14 |
| CN101052416B (zh) | 2013-07-10 |
| RU2519340C2 (ru) | 2014-06-10 |
| EP2497497B1 (en) | 2017-06-21 |
| BRPI0512854A (pt) | 2008-04-08 |
| WO2006002889A2 (en) | 2006-01-12 |
| KR20070036085A (ko) | 2007-04-02 |
| KR101205289B1 (ko) | 2012-11-27 |
| EP1763367A2 (en) | 2007-03-21 |
| ES2641089T3 (es) | 2017-11-07 |
| MXPA06013240A (es) | 2007-02-28 |
| EP2497497A1 (en) | 2012-09-12 |
| RU2007104040A (ru) | 2008-08-10 |
| AU2005259481A1 (en) | 2006-01-12 |
| CN101052416A (zh) | 2007-10-10 |
| WO2006002889A3 (en) | 2006-10-05 |
| JP2008505143A (ja) | 2008-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2519340C2 (ru) | Улучшенная вспомогательная терапия опухолей, экспрессирующих g250 | |
| Postow et al. | Mucosal melanoma: pathogenesis, clinical behavior, and management | |
| Chung et al. | Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma | |
| Yamamoto et al. | Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021 | |
| CN108026173A (zh) | 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症 | |
| Lutt et al. | Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis | |
| Lin et al. | Immune microenvironment of primary and recurrent craniopharyngiomas: A study of the differences and clinical significance | |
| Weber et al. | Personalizing locoregional therapy in patients with breast cancer in 2024: tailoring axillary surgery, escalating lymphatic surgery, and implementing evidence-based hypofractionated radiotherapy | |
| Herlyn et al. | Initial clinical evaluation of two murine IgG2a monoclonal antibodies for immunotherapy of gastrointestinal carcinoma | |
| Pervez et al. | Localization of monoclonal antibody auai and its F (ab') 2 fragments in human tumour xenografts: An autoradiographic and immunohistochemical study | |
| Freedman et al. | Solitary late recurrence of renal cell carcinoma presenting as duodenal ulcer | |
| Imundo | Hodgkin’s lymphoma associated with anti-tumor necrosis factor use in juvenile idiopathic arthritis: Supplemental case report | |
| Yildirim-Toruner et al. | Hodgkin’s lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis | |
| Song et al. | Blocking transforming growth factor-beta reduces the migration and invasion of the residual tumour after TAE | |
| Takenami et al. | Efficacy of neoadjuvant chemotherapy with capecitabine plus oxaliplatin in the treatment of locally advanced sigmoid colon cancer invading the urinary bladder: a report of three cases | |
| Ames et al. | Imatinib treatment of seropositive arthritis in a young woman with chronic myeloid leukemia | |
| Bao et al. | Advanced cholangiocarcinoma with human epidermal growth factor receptor 2 (HER2) amplification treated with Trastuzumab deruxtecan (T-DXd): A case report | |
| Yamamoto et al. | Fibrin-associated diffuse large B-cell lymphoma arising in an abdominal aortic graft: A case report and literature review | |
| CN102935228A (zh) | 用于肿瘤治疗的试剂、其用途及方法 | |
| Ohta et al. | Case Report: Severe neutropenia induced by avelumab in a patient with Merkel cell carcinoma | |
| Mahipal et al. | Gallbladder Cancer | |
| Li et al. | Disitamab vedotin (RC48) long-term regimen in a post-nephroureterectomy patient with metastases: a case report | |
| House | Adjuvant therapy in colorectal cancer | |
| Kast et al. | Both etanercept and infliximab can elevate tumor necrosis factor (TNF)-α and be the cause of treatment related new onset disease: the need to measure circulating TNF-α | |
| HK40034183A (en) | Use of anti-her2 antibody-drug conjugate in cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20190630 |